Bangladesh Generic Trikafta Imports Cut Annual CF Drug Costs from $322000 to Under $10000 via Compulsory Licensing Loophole

The pathway exploits national compulsory licensing provisions and personal importation rules that allow small-batch procurement of the triple CFTR modulator without Vertex authorization. Families in Canada, the UK, and Australia have documented shipments arriving within 4-6 weeks, with potency assays confirming bioequivalence to the branded product in independent lab tests. This development follows Vertex's refusal to license in low-volume markets despite 2024 sales exceeding $9 billion.

Three observational cohorts totaling 187 patients show sustained FEV1 gains of 8-12 percentage points at 6 months and reduced pulmonary exacerbations, matching phase 3 trial effect sizes reported in the New England Journal of Medicine. However, no randomized data yet exist on long-term adherence or resistance patterns under generic supply chains. Regulatory agencies have issued no formal safety alerts but require individual import notifications.

The case exposes how high-income pricing strategies create parallel gray-market channels that regulators have tacitly tolerated for orphan drugs. Similar dynamics occurred with sofosbuvir generics from India after 2015, yet CFTR modulators lack comparable voluntary licensing frameworks. Payers in the US remain constrained by FDA rules against routine personal importation of patented agents.

Next steps hinge on whether Vertex pursues litigation against Bangladeshi manufacturers or negotiates volume-based concessions. A forthcoming FDA advisory committee meeting in September 2026 will examine expanded importation criteria for high-cost rare-disease therapies.